Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

Clinical Rheumatology

Volumn 33, Issue 6, 2014, Pages 833-839

  Costa, Luisa ^a,b   Caso, Francesco ^b   Atteno, Mariangela ^a   Del Puente, Antonio ^a   Darda, Md Abud ^b   Caso, Paolo ^c   Ortolan, Augusta ^b   Fiocco, Ugo ^b   Ramonda, Roberta ^b   Punzi, Leonardo ^b   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adalimumab; Anti TNF ; Etanercept; Metabolic syndrome; Methotrexate; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHOTREXATE; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE; WAIST CIRCUMFERENCE; ADIPOCYTE; ADULT; APOPTOSIS; ARTHRITIS, PSORIATIC; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; CYTOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADIPOCYTES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; METABOLIC SYNDROME X; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903815067     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2369-1     Document Type: Article

References (37)

1. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55-78
2. Scarpa R, Altomare G, Marchesoni A, Balato N, Matucci Cerinic M, Lotti T, Olivieri I, Vena GA, Salvarani C, Valesini G, Giannetti A (2010) Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol 24:627-630
3. Ritchlin CT (2008) From skin to bone: translational perspectives on psoriatic disease. J Rheumatol 35:1434-1437
4. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195-202
5. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331-334
6. Pereira RM, de Carvalho JF, Bonfá E (2009) Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8:415-419
7. Raychaudhuri SP (2012) Comorbidities of psoriatic arthritis - metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 39:437-440
8. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2012) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202325
9. Zhu TY, Li EK, Tam LS (2012) Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012:714321
10. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, Punzi L, Doria A (2011) Atherosclerosis in psoriatic arthritis. Autoimmun Rev 10:773-778
11. Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14:343-348
12. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM (2012) Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 51:2215-2223
13. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711-715
14. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, Matucci-Cerinic M, Sitia S, Tomasoni L, Turiel M (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849-852
15. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology 47:718-723 (Pubitemid 351619219)
16. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904-909
17. Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, Bernardi D, Ramonda R, Plebani M, Punzi L (2009) Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 27:79-83
18. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415-1428 (Pubitemid 40523737)
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
20. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235-240 (Pubitemid 44894605)
21. Scrivo R, Vasile M, Bartosiewicz I, Valesini G (2011) Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev 10:369-374
22. Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-355 (Pubitemid 40277057)
23. Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346-357 (Pubitemid 37211389)
24. Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19-29 (Pubitemid 129505535)
25. Fonseca JE, Santos MJ, Canhão H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538-542
26. Mease PJ (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298-304
27. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524-528 (Pubitemid 47374613)
28. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A (2011) Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 10:631-635
29. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33:2440-2446 (Pubitemid 46067823)
30. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K (2002) Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114:1004-1007 (Pubitemid 36105546)
31. Stinco G, Piccirillo F, Patrone P (2007) Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 157:1273-1274 (Pubitemid 350115672)
32. Castro KR, Aikawa NE, Saad CG, Moraes JC, Medeiros AC, Mota LM, Silva CA, Bonfá E, Carvalho JF (2011) Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol 2011:352686
33. Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC (2006) Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 29:1712-1713 (Pubitemid 44127614)
34. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665-2673 (Pubitemid 44205029)
35. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48-53
36. Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62:965-969
37. Gremese E, Ferraccioli G (2011) The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10:582-589